Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation TCT 2025

Continuous, Non-Invasive Left Ventricular Volume Monitoring for Next-Generation Hemodynamic Monitoring (SensVita)

Presenter: Thomas Conroy

October 27, 2025

Presentation TCT 2022

TCT 31: Clinical Impact of Genetics on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention Using Drug-Eluting Stent

Presenter: Seung Hun Lee

September 19, 2022

Presentation TCT 2022

TCT 19: Thrombin Generation and Endothelial Progenitor Cell Function in Patients with Acute Myocardial Infarction Treated with Prasugrel versus Ticagrelor

Presenter: Mark Kheifets

September 17, 2022

Session XI: Future Directions and Challenges in the MedTech Field - Featured Technology: Real-World Evidence Generation Technology Using Artificial Intelligence and Deep Learning to Predict Disease Risk and Efficacy of Therapy (HOLMUSK)

Presentation TCT 2019

Featured Technology: Real-World Evidence Generation Technology Using Artificial Intelligence and Deep Learning to Predict Disease Risk and Efficacy of Therapy (HOLMUSK)

Presenter: Joydeep Sarkar

September 26, 2019

Presentation TCT 2018

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

Presenter: Dominick J. Angiolillo, Elmir Omerovic, Duk-Woo Park

September 23, 2018

Presentation TCT 2017

Shockwave Therapy for Calcified Coronary Lesions: Device, Data, and Case Reviews

Presenter: Salvatore Brugaletta, Philippe Genereux, Jonathan M. Hill

November 01, 2017

Presentation TCT 2016

Beyond Cells: Cardiac Gene Therapy In Perspective

Presenter: Emerson C. Perin, Marc S. Penn

October 31, 2016

Presentation TCT 2016

Duration of DAPT Therapy With Contemporary DES (Including BVS)

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Gustavo A Samaja

October 31, 2016

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

Gene Therapy for CHF

Presenter: Henricus J. Duckers, Bernard J. Gersh, Gary L. Schaer

October 14, 2015

Presentation TCT 2014

Gene Therapy to Reverse Remodel the Failing Heart: State of the Art

Presenter: Vasken Dilsizian, Sunil V. Rao, Jose P.S. Henriques, Krisztina Zsebo

September 15, 2014

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

Effective Antegrade Cardiac Gene Therapy with VEGF-B167 for Pacing-induced Dilated Cardiomyopathy in a Pre-clinical Large Animal Model of Heart Failure

Presenter: Felix Woitek

October 29, 2013

Presentation TCT 2013

The Genesis of Local Therapy: Catheter-directed Thrombolysis

Presenter: Thomas McNamara

October 27, 2013

Presentation TCT 2012

Gene Therapy for Peripheral Arterial Disease: Status Update

Presenter: Timothy Henry

October 22, 2012

Advertisement

Continuous, Non-Invasive Left Ventricular Volume Monitoring for Next-Generation Hemodynamic Monitoring (SensVita)

TCT 31: Clinical Impact of Genetics on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention Using Drug-Eluting Stent

TCT 19: Thrombin Generation and Endothelial Progenitor Cell Function in Patients with Acute Myocardial Infarction Treated with Prasugrel versus Ticagrelor

Featured Technology: Real-World Evidence Generation Technology Using Artificial Intelligence and Deep Learning to Predict Disease Risk and Efficacy of Therapy (HOLMUSK)

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

Shockwave Therapy for Calcified Coronary Lesions: Device, Data, and Case Reviews

Beyond Cells: Cardiac Gene Therapy In Perspective

Duration of DAPT Therapy With Contemporary DES (Including BVS)

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Gene Therapy for CHF

Gene Therapy to Reverse Remodel the Failing Heart: State of the Art

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Effective Antegrade Cardiac Gene Therapy with VEGF-B167 for Pacing-induced Dilated Cardiomyopathy in a Pre-clinical Large Animal Model of Heart Failure

The Genesis of Local Therapy: Catheter-directed Thrombolysis

Gene Therapy for Peripheral Arterial Disease: Status Update

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content